Deutsche Bank AG Decreases Stake in AnaptysBio, Inc. $ANAB

Deutsche Bank AG cut its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 11.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,796 shares of the biotechnology company’s stock after selling 2,071 shares during the period. Deutsche Bank AG owned 0.05% of AnaptysBio worth $294,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Fairmount Funds Management LLC purchased a new position in shares of AnaptysBio during the fourth quarter valued at approximately $24,050,000. Boxer Capital Management LLC purchased a new position in shares of AnaptysBio during the fourth quarter valued at approximately $17,212,000. Sanofi purchased a new position in shares of AnaptysBio during the fourth quarter valued at approximately $10,882,000. Woodline Partners LP increased its stake in shares of AnaptysBio by 5.5% during the fourth quarter. Woodline Partners LP now owns 485,073 shares of the biotechnology company’s stock valued at $6,422,000 after buying an additional 25,094 shares during the period. Finally, Soleus Capital Management L.P. purchased a new position in shares of AnaptysBio during the fourth quarter valued at approximately $5,481,000.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ANAB shares. Guggenheim reissued a “buy” rating and set a $90.00 target price (up from $54.00) on shares of AnaptysBio in a research note on Wednesday, May 28th. UBS Group reaffirmed a “neutral” rating and issued a $20.00 price target (up from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. JPMorgan Chase & Co. upped their price target on AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. HC Wainwright raised AnaptysBio from a “neutral” rating to a “buy” rating and upped their price target for the stock from $22.00 to $38.00 in a research note on Wednesday, June 4th. Finally, Wedbush upped their price target on AnaptysBio from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $46.13.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB opened at $20.33 on Friday. The company has a market cap of $569.24 million, a P/E ratio of -4.54 and a beta of -0.20. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $40.70. The stock’s fifty day moving average price is $23.31 and its 200-day moving average price is $20.85.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.16. The firm had revenue of $22.26 million for the quarter, compared to the consensus estimate of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. On average, sell-side analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

Insider Activity

In other news, Director Hollings Renton sold 20,925 shares of the company’s stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total transaction of $493,202.25. Following the transaction, the director directly owned 4,965 shares of the company’s stock, valued at $117,025.05. This represents a 80.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 33.50% of the stock is currently owned by insiders.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.